How much does it cost to include bedaquiline fumarate (Snaery) in medical insurance?

Bedaquiline fumarate (Bedaquiline) is a new anti-tuberculosis drug that is considered an important breakthrough in the treatment of tuberculosis in recent years. Tuberculosis, an infectious disease caused by Mycobacterium tuberculosis, has long been one of the major challenges to global public health. The overuse and abuse of traditional anti-tuberculosis drugs has led to increasing resistance of Mycobacterium tuberculosis to these drugs, necessitating the urgent need for new treatments.

Bedaquiline (Snaery) has now been launched in the domestic market and has also been included in the medical insurance system. Patients can purchase it domestically. For the specifications of 100mg*24 tablets, the price is about four to five thousand yuan. However, for specific selling price information and medical insurance reimbursement details, please contact the local hospital pharmacy for detailed consultation.

Also, if you are looking for a more economical option, the Russian version of the original drug is a good choice. This drug maintains exactly the same efficacy as the domestic Bedaquiline (Sneril) at a more affordable price. For the specifications of 100mg*188 tablets, the price is about more than 10,000 yuan. Compared with the domestic market, the price/performance ratio is significantly improved.

Bedaquiline (Snaeryx) is the first new drug approved to treat multidrug-resistant tuberculosis (MDR-TB ). MDR-TB is a severe form of tuberculosis that is resistant to conventional tuberculosis treatment drugs. It is difficult to treat and has poor efficacy, posing a serious threat to patient survival and public health. The emergence of bedaquiline (Sneril) has filled the gap in the treatment field of MDR-TB and provided new hope for patients.

The mechanism of action of bedaquiline (Snaery) is to block the growth of Mycobacterium tuberculosis by inhibiting the activity of ATP synthase, thereby achieving therapeutic effects. Compared with traditional anti-tuberculosis drugs, bedaquiline (Snaery) is more selective and effective, can more effectively eliminate drug-resistant strains, and reduce the risk of treatment failure and disease recurrence.